What is Respiri?
Respiri Limited operates as a specialized e-health SaaS enterprise, focusing on the research, development, and commercialization of advanced medical devices and mobile health applications. Headquartered in Melbourne, Australia, the firm is best known for its flagship product, Wheezo, an innovative asthma management tool. This platform empowers patients by tracking triggers, symptoms, and medication adherence, effectively bridging the gap between clinical monitoring and daily patient self-management. Formerly known as iSonea Limited, the company rebranded in 2015 to better reflect its commitment to respiratory health innovation across its primary markets in Australia and Israel.
How much funding has Respiri raised?
Respiri has raised a total of $12.5M across 1 funding round:
Stock Offering
$12.5M
Stock Issuance/Offering (2020): $12.5M, investors not publicly disclosed
Key Investors in Respiri
Respiri
Undisclosed investor participating in the funding round.
What's next for Respiri?
With the recent influx of capital, Respiri is poised to transition into a more aggressive growth phase, focusing on the widespread adoption of its digital health ecosystem. The strategic roadmap likely involves enhancing the data analytics capabilities of the Wheezo platform to provide deeper clinical insights for healthcare providers. Furthermore, the company is expected to prioritize market penetration strategies, leveraging its recent financing to scale operations and potentially explore new therapeutic areas within the respiratory health domain. As the digital health sector continues to mature, Respiri's focus on evidence-based mobile health solutions will be critical in maintaining its competitive advantage and driving long-term shareholder value.
See full Respiri company page
